2,5-Dimethyl-4-ethyl-pyridin | 74304-03-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,5-Dimethyl-4-ethyl-pyridin
• 英文别名: 4-ethyl-2,5-dimethyl-pyridine；2,5-Dimethyl-4-ethylpyridine；4-ethyl-2,5-dimethylpyridine
• CAS: 74304-03-3
• 化学式: C₉H₁₃N
• 分子量: 135.209
• InChiKey: JBNJDXSYIBJKBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• COVALENT INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20140288045A1

  公开（公告）日：2014-09-25

  Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

  G12C突变K-Ras蛋白的不可逆抑制剂已提供。还公开了调节G12C突变K-Ras蛋白活性的方法以及通过G12C突变K-Ras蛋白介导的疾病治疗方法。
• [EN] COMBINATION THERAPIES FOR TREATMENT OF CANCER<br/>[FR] THÉRAPIES COMBINATOIRES POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2016044772A1

  公开（公告）日：2016-03-24

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

  提供用于治疗与KRAS基因突变相关的癌症的联合疗法。还提供了包含治疗剂的组合物，用于治疗与KRAS基因突变相关的癌症。
• [EN] COMPOSITIONS AND METHODS FOR INHIBITION OF RAS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR INHIBER LA RAS
  申请人：ARAXES PHARMA LLC

  公开号：WO2016049565A1

  公开（公告）日：2016-03-31

  Inhibitors of Ras protein; methods to modulate the activity of Ras protein; and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, HRas or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as pancreatic cancer, colon cancer, MYH associated polyposis, colorectal cancer, lung cancer or NSCLC.

  提供了Ras蛋白的抑制剂；调节Ras蛋白活性的方法；以及治疗由Ras蛋白介导的疾病的方法。描述了一种使用化合物调节K-Ras、HRas或N-Ras突变蛋白活性的方法。可治疗的疾病包括癌症，如胰腺癌、结肠癌、MYH相关性息肉病、结直肠癌、肺癌或非小细胞肺癌。
• COMBINATION THERAPIES FOR TREATMENT OF CANCER
  申请人：Araxes Pharma LLC

  公开号：US20160166571A1

  公开（公告）日：2016-06-16

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

  提供了用于治疗与KRAS基因突变相关的癌症的联合治疗方案。还提供了包含治疗剂的组合物，用于治疗与KRAS基因突变相关的癌症。
• THERMOSETTABLE POLYSTYRYLPYRIDINE PREPOLYMER TERMINATED WITH ETHYLENICALLY UNSATURATED GROUPS AND CURED PRODUCTS THEREFROM
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0220204A1

  公开（公告）日：1987-05-06